Albany Molecular Research (AMRI) Stock Price, News & Analysis

Company Overview

Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Key Stats

• Today's Range: $21.74 to $21.74
• 50-Day Range: $21.74 to $21.74
• 52-Week Range: $13.01 to $22.17
• Volume: N/A
• Average Volume: 872,120 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMRI Stock Analysis - Frequently Asked Questions

How were Albany Molecular Research's earnings last quarter?

Albany Molecular Research Inc (NASDAQ:AMRI) released its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.21 by $0.14. The biotechnology company had revenue of $102.80 million for the quarter, compared to analyst estimates of $107.20 million.

What other stocks do shareholders of Albany Molecular Research own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Albany Molecular Research investors own include Casella Waste Systems (CWST), Bristol Myers Squibb (BMY), Zevra Therapeutics (KMPH), Teva Pharmaceutical Industries (TEVA), Allergan (AGN), Alpha Lithium (APHLF) and Denison Mine (DNN).

Company Calendar

• Last Earnings: 5/10/2016
• Today: 8/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AMRI
• CIK: 1065087
• Web: www.amriglobal.com
• Phone: +1-518-4640279
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A